What Has Been the Progress and Growth of the Liposomal Doxorubicin Market in Recent Years?
The liposomal doxorubicin market has seen considerable growth due to a variety of factors.
• The liposomal doxorubicin market has seen strong growth in recent years. It will grow from $1.23 billion in 2024 to $1.32 billion in 2025, at a CAGR of 7.2%.
This growth is driven by improvements in liposome formulations, favorable cancer treatment reimbursement policies, greater awareness of cancer screening, better healthcare infrastructure, and the increasing preference for minimally invasive cancer treatments.
What Can Be Expected from the Liposomal Doxorubicin Market Size?
The liposomal doxorubicin market is expected to maintain its strong growth trajectory in upcoming years.
• The liposomal doxorubicin market is expected to reach $1.72 billion by 2029, growing at a CAGR of 6.8%.
The growth is attributed to the increasing awareness about cancer treatments, rising clinical trials, adoption of combination therapies, and growing preference for targeted therapies. Trends include AI and machine learning in drug discovery, 3D printing, magnetic targeting, and advancements in drug delivery.
What Are the Critical Driver Fuelling The Liposomal Doxorubicin Market's Growth?
The increasing prevalence of cancer is expected to drive the growth of the liposomal doxorubicin market. Cancer, a disease marked by uncontrolled cell growth, is becoming more widespread due to aging populations, lifestyle changes, and environmental factors. Liposomal doxorubicin is used in cancer treatments to enhance drug delivery to tumors, reduce toxicity, and improve therapeutic outcomes. The American Cancer Society reported that the number of cancer cases rose by 2.19% from 2023 to 2024, reaching 2,001,140. Therefore, the increasing prevalence of cancer is fueling the growth of the liposomal doxorubicin market.
How Is The Liposomal Doxorubicin Market segmented?
The liposomal doxorubicin market covered in this report is segmented –
1) By Product: Doxil Or Caelyx, Lipodox, Myocet, Other Products
2) By Route Of Administration: Parenteral, Other Routes Of Administration
3) By Application: Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, Other Applications
4) By End-Users: Hospitals, Homecare, Other End-Users
Subsegments:
1) By Doxil Or Caelyx: Different Dosage Strengths, Branded Versions, Generic Versions
2) By Lipodox: Different Dosage Strengths, Branded Versions, Generic Versions
3) By Myocet: Different Dosage Strengths, Branded Versions, Generic Versions
4) By Other Products: Newer Liposomal Formulations, Regional Brand Variants, Combination Therapies
Pre-Book The Liposomal Doxorubicin Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Liposomal Doxorubicin Market?
Leading firms in the liposomal doxorubicin market, like Accord Healthcare Limited, are concentrating their efforts on creating improved drug delivery systems like PEGylated liposomes. Their aim is to enhance the pharmacokinetics and biodistribution of doxorubicin, resulting in improved outcomes for patients. This progress serves to increase both the efficiency and accuracy of drug delivery, confirming that medicines are accurately directed at cancer cells while limiting adverse side effects. For example, in May 2022, the US-based pharmaceutical company Accord Healthcare Limited launched Zolsketil, a pegylated liposomal 2mg/ml concentrate for dispersion for infusion. This product is a generic variant of the widely used cancer medication doxorubicin, which is utilized to treat a variety of cancer forms.
Who Are the Key Players In The Liposomal Doxorubicin Market?
Major companies operating in the liposomal doxorubicin market are:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd
• Baxter International Inc.
• Astellas Pharma
• Sun Pharmaceutical Industries Ltd
• Jazz Pharmaceuticals
• Cipla Inc.
• Endo Pharmaceuticals
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Zydus Cadila
• Accord Healthcare Limited
• Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
• TTY Biopharm Company Limited
• SRS Life Sciences
What Is The Most Dominant Region In The Liposomal Doxorubicin Market?
North America was the largest region in the liposomal doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
